Pharmaceuticals & Life Sciences

Cloud Migration for Pharmaceuticals & Life Sciences

Cloud Migration for pharmaceuticals & life sciences, built around the constraint that defines the sector: GxP validation means every system change needs documented evidence before it reaches production.

Regulations in scope
5
Systems we integrate
5
Typical first release
6 weeks

What changes when it is pharmaceuticals & life sciences

The first cloud bill surprises people. We build cost monitoring and right-sizing into the migration rather than treating it as a later clean-up exercise.

In pharmaceuticals & life sciences, GxP validation means every system change needs documented evidence before it reaches production. That single fact reshapes how cloud migration has to be built here, the guardrails, the approval points and the evidence trail are design inputs rather than things bolted on before go-live.

The workload we are most often asked to take on first is deviation and CAPA drafting, usually integrated against pharmacovigilance databases. Every engagement opens with a measurement: the cycle time, the cost per transaction, or the error rate we are being asked to move.

Deployed across regulated and unregulated sectors, with audit trails where the regulator expects them. We hand over with runbooks, tests and a team that knows how it works, not a dependency.

The sector constraints we design around

Defining constraint
GxP validation means every system change needs documented evidence before it reaches production
Regulations in scope
CDSCO · US FDA 21 CFR Part 11 · EU GMP Annex 11 · GxP validation · ICH guidelines
Systems of record
LIMS · QMS · eTMF · SAP · pharmacovigilance databases
Where we usually start
batch record review

Cloud Migration workloads in pharmaceuticals & life sciences

  • batch record review
  • adverse event intake and coding
  • regulatory dossier assembly
  • deviation and CAPA drafting
  • literature monitoring

What is included

  • Inventory of every workload, dependency and integration before planning
  • Cost model comparing current spend against realistic cloud spend
  • Migration approach per workload rather than one strategy for all
  • Staged cutover with rollback at each step
  • Security posture, network design and access control
  • Post-migration cost optimisation, because the first bill is never the last word

Questions from this sector

Can an AI system be GxP validated?

Yes, with a documented validation approach, IQ/OQ/PQ, defined intended use, change control and evidence of consistent performance. We build the validation pack alongside the system, not afterwards.

How do you handle 21 CFR Part 11?

Audit trails, electronic signatures, access control and record integrity designed in from the start, because retrofitting them is effectively a rebuild.

Will cloud reduce our costs?

Sometimes, and not automatically. Variable and spiky workloads usually save; steady heavy compute often does not. The cost model in week one gives you the real answer for your estate.

Can we migrate without downtime?

For most workloads, yes, with staged cutover and parallel running. Some database migrations need a short planned window, which we rehearse rather than improvise.

Should we go multi-cloud?

Rarely, unless you have a specific reason. Multi-cloud doubles operational complexity and most organisations do not recover that cost in resilience or leverage.

Cloud Migration for pharmaceuticals & life sciences, worth a conversation?

Tell us the workload and the regulation it sits under. We will tell you what is realistic.

Or email bd@dtrasglobal.com · call +91 74118 77878